Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Proinflammatory cytokines are potent mediators of numerous biological processes and are tightly regulated in the body. Chronic uncontrolled levels of such cytokines can initiate and derive many pathologies, including incidences of autoimmunity and cancer. Therefore, therapies that regulate the activity of inflammatory cytokines, either by supplementation of anti-inflammatory recombinant cytokines or by neutralizing them by using blocking antibodies, have been extensively used over the past decades. Over the past few years, new innovative biological agents for blocking and regulating cytokine activities have emerged. Here, we review some of the most recent approaches of cytokine targeting, focusing on anti-TNF antibodies or recombinant TNF decoy receptor, recombinant IL-1 receptor antagonist (IL-1Ra) and anti-IL-1 antibodies, anti-IL-6 receptor antibodies, and TH17 targeting antibodies. We discuss their effects as biologic drugs, as evaluated in numerous clinical trials, and highlight their therapeutic potential as well as emphasize their inherent limitations and clinical risks. We suggest that while systemic blocking of proinflammatory cytokines using biological agents can ameliorate disease pathogenesis and progression, it may also abrogate the hosts defense against infections. Moreover, we outline the rational need to develop new therapies, which block inflammatory cytokines only at sites of inflammation, while enabling their function systemically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These AEs are frequently observed in biologics targeting immune checkpoints, or cytokines (Rider et al., 2016; Postow et al., 2018).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Rider et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099 · cited 1×
“Previously termed “IL-23-derived autoreactive CD4 T cells,” TH17 cells were named after IL-17 cytokine (which they produce) and are correlated with autoimmunity disorders including RA, lupus, colitis, and EAE [125, 126].”
BackgroundAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Increased expression of interleukin 17 in inflammatory bowel disease
Fujino, S., Andoh, A., Bamba, S., Ogawa, A., Hata, K., Araki, Y., Bamba, T., & Fujiyama, Y. (2003) · Gut · doi:10.1136/gut.52.1.65 · Cited by 1,713
Signal transduction by tumor necrosis factor and its relatives
Baud, V., & Karin, M. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02064-5 · Cited by 1,655
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Tumor Necrosis Factor-α Signaling in Macrophages
Parameswaran, N., & Patial, S. (2010) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v20.i2.10 · Cited by 1,437
Angiogenesis and Inflammation in Peritoneal Dialysis: The Role of Adipocytes
Shi, J., Yu, M., & Sheng, M. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000476017 · Cited by 1,403
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J., Kliewer, E. V., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<785::aid-cncr1065>3.0.co;2-r · Cited by 1,179
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
Rosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Eisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., & Thompson, R. C. (1990) · Nature · doi:10.1038/343341a0 · Cited by 1,088
Course and outcome of hepatitis C
Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360704 · Cited by 1,084
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.
Auron, P. E., Webb, A. C., Rosenwasser, L. J., Mucci, S. F., Rich, A., Wolff, S. M., & Dinarello, C. A. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.24.7907 · Cited by 1,042
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029
An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist
Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgård, U., Cowen, E. W., Pham, T.-H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 987
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Pascual, V., Allantaz, F., Arce, E., Punaro, M., & Banchereau, J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050473 · Cited by 922
Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., Catrina, A. I., Rosenquist, R., Feltelius, N., Sundström, C., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21675 · Cited by 890
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Houssiau, F. A., Devogelaer, J., Damme, J. V., Deuxchaisnes, C. N. D., & Snick, J. V. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310614 · Cited by 847
Mohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G., Stremler, K. E., Fung, V. P., Madani, H., & Widmer, M. B. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.3.1548 · Cited by 832
Paraneoplastic thrombocytosis in ovarian cancer
Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110352 · Cited by 812
Treatment of Acute Hepatitis C with Interferon Alfa-2b
Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., & Manns, M. P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011232 · Cited by 800
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789 · cited 5×
“Anakinra was also shown to be effective in the case of nonhereditary chronic systemic inflammatory diseases like the adult-onset Still disease [63, 64], which involves arthritis, fever, and systemic inflammation or the childhood version—systemic-onset juvenile idiopathic arthritis (SJIA) [65–67].”
BackgroundInfluentialSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
A pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727 · cited 1×
“Like anakinra, both were shown to reduce symptoms in additional inflammatory diseases, such as gout [87, 88], and canakinumab was also shown to be effective for SJIA.”
BackgroundTwo Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Ruperto, N., Brunner, H. I., Quartier, P., Constantin, T., Wulffraat, N., Horneff, G., Brik, R., McCann, L., Kasapcopur, O., Rutkowska-Sak, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205099 · Cited by 713
Inflammasome activation and IL-1β and IL-18 processing during infection
van de Veerdonk, F. L., Netea, M. G., Dinarello, C. A., & Joosten, L. A. B. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.01.003 · Cited by 691
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
Treating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Wolfe, F., & Michaud, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20311 · Cited by 644
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor
Wang, A. M., Creasey, A. A., Ladner, M. B., Lin, L. S., Strickler, J., Van Arsdell, J. N., Yamamoto, R., & Mark, D. F. (1985) · Science · doi:10.1126/science.3856324 · Cited by 622
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., Bossuyt, X., Boutten, A., Bienvenu, J., Duquesne, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134254 · Cited by 558
Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., Anderson, J. P., Wanderer, A. A., & Firestein, G. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17401-1 · Cited by 552
Engelmann, H., Novick, D., & Wallach, D. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40049-5 · Cited by 549
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Strangfeld, A. (2009) · JAMA · doi:10.1001/jama.2009.146 · Cited by 542
IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation
Rider, P., Carmi, Y., Guttman, O., Braiman, A., Cohen, I., Voronov, E., White, M. R., Dinarello, C. A., & Apte, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102048 · Cited by 522
Self-citationCourse and outcome of hepatitis C
Hoofnagle, J. H. (2002) · Hepatology · doi:10.1053/jhep.2002.36227 · Cited by 509
Mackey, A. C., Green, L., Liang, L., Dinndorf, P., & Avigan, M. (2007) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31802f6424 · Cited by 506
Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor
Shirai, T., Yamaguchi, H., Ito, H., Todd, C. W., & Wallace, R. B. (1985) · Nature · doi:10.1038/313803a0 · Cited by 459
Abbate, A., Kontos, M. C., Grizzard, J. D., Biondi-Zoccai, G. G. L., Van Tassell, B. W., Robati, R., Roach, L. M., Arena, R. A., Roberts, C. S., Varma, A., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.12.059 · Cited by 415
Molecular Pathways Linking Inflammation and Cancer
Mantovani, A. (2010) · Current Molecular Medicine · doi:10.2174/156652410791316968 · Cited by 414
Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor.
Pennica, D., Hayflick, J. S., Bringman, T. S., Palladino, M. A., & Goeddel, D. V. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6060 · Cited by 390
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Integrated safety in tocilizumab clinical trials
Schiff, M. H., Kremer, J. M., Jahreis, A., Vernon, E., Isaacs, J. D., & van Vollenhoven, R. F. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3455 · Cited by 367
Schlesinger, N., Alten, R. E., Bardin, T., Schumacher, H. R., Bloch, M., Gimona, A., Krammer, G., Murphy, V., Richard, D., & So, A. K. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200908 · Cited by 359
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
Fitzgerald, A. A., LeClercq, S. A., Yan, A., Homik, J. E., & Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21061 · Cited by 350
Anakinra for Rheumatoid Arthritis: A Systematic Review
MERTENS, M., & SINGH, J. A. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090074 · Cited by 344
Risk of malignancy among patients with rheumatic conditions
Thomas, E., Brewster, D. H., Black, R. J., & Macfarlane, G. J. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001101)88:3<497::aid-ijc27>3.0.co;2-j · Cited by 332
Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., Voronov, E., Martin, M. U., Dinarello, C. A., & Apte, R. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915018107 · Cited by 329
Self-citationInflammasome-independent regulation of IL-1-family cytokines
Netea, M. G., van de Veerdonk, F. L., van der Meer, J. W. M., Dinarello, C. A., & Joosten, L. A. B. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112306 · Cited by 326 · cited 1×
“In the inflammatory sites, increased levels of neutrophil serine proteases (like elastase, cathepsin G, or chymotrypsin) [139], macrophagesderived PR3 and caspase-1 [140, 141], or granzymes from NK cells [142] are released from activated or dying cells and these enzymes cleave the N-terminal peptide of IL-1β and relea…”
BackgroundIL-1 Blockade in Autoinflammatory Syndromes
Jesus, A. A., & Goldbach-Mansky, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061512-150641 · Cited by 326
Arend, W. P., Joslin, F. G., & Massoni, R. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3868 · Cited by 322
Inflammation by remote control
Mantovani, A. (2005) · Nature · doi:10.1038/435752a · Cited by 313
Joosten, L. A. B., Netea, M. G., Fantuzzi, G., Koenders, M. I., Helsen, M. M. A., Sparrer, H., Pham, C. T., van der Meer, J. W. M., Dinarello, C. A., & van den Berg, W. B. (2009) · Arthritis & Rheumatism · doi:10.1002/art.25006 · Cited by 296
The Inflammasomes and Autoinflammatory Syndromes
Broderick, L., De Nardo, D., Franklin, B. S., Hoffman, H. M., & Latz, E. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040431 · Cited by 295
Kauffman, C. L., Aria, N., Toichi, E., McCormick, T. S., Cooper, K. D., Gottlieb, A. B., Everitt, D. E., Frederick, B., Zhu, Y., Graham, M. A., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23448.x · Cited by 279
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression
Fransen, L., Mūller, R., Marmenout, A., Tavernier, J., Heyden, J. V. D., Kawashima, E., Chollet, A., Tizard, R., Heuverswyn, H. V., Vliet, A. V., et al. (1985) · Nucleic Acids Research · doi:10.1093/nar/13.12.4417 · Cited by 263
Atreya, R., Zimmer, M., Bartsch, B., Waldner, M. J., Atreya, I., Neumann, H., Hildner, K., Hoffman, A., Kiesslich, R., Rink, A. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.032 · Cited by 256
A human inhibitor of tumor necrosis factor alpha.
Seckinger, P., Isaaz, S., & Dayer, J. M. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.4.1511 · Cited by 255
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 246
Granzyme A is an interleukin 1 beta-converting enzyme.
Irmler, M., Hertig, S., MacDonald, H. R., Sadoul, R., Becherer, J. D., Proudfoot, A., Solari, R., & Tschopp, J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1917 · Cited by 227
The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis
Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M. A., Fogel, M., Huszar, M., White, M. R., Dinarello, C. A., & Apte, R. N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901511 · Cited by 224
Self-citationThe Role of IL-1β in the Early Tumor Cell–Induced Angiogenic Response
Carmi, Y., Dotan, S., Rider, P., Kaplanov, I., White, M. R., Baron, R., Abutbul, S., Huszar, M., Dinarello, C. A., Apte, R. N., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202769 · Cited by 209
Self-citationMeinzer, U., Quartier, P., Alexandra, J.-F., Hentgen, V., Retornaz, F., & Koné-Paut, I. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.11.003 · Cited by 205
Nishimoto, N., Yoshizaki, K., Maeda, K., Kuritani, T., Deguchi, H., Sato, B., Imai, N., Suemura, M., Kakehi, T., Takagi, N., et al. (2003) · PubMed · Cited by 203
Hong, D. S., Hui, D., Bruera, E., Janku, F., Naing, A., Falchook, G. S., Piha-Paul, S., Wheler, J. J., Fu, S., Tsimberidou, A. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70155-x · Cited by 199
Demyelination and other neurological adverse events after anti-TNF therapy
Kaltsonoudis, E., Voulgari, P. V., Konitsiotis, S., & Drosos, A. A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.09.002 · Cited by 184
Molecular and cellular biology of interleukin-6 and its receptor
Keller, E. T. (1996) · Frontiers in Bioscience · doi:10.2741/a136 · Cited by 182
Anakinra for rheumatoid arthritis
Mertens, M., & Singh, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005121.pub3 · Cited by 179
KOJ, A. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb23994.x · Cited by 177
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
Cavalli, G., & Dinarello, C. A. (2015) · Rheumatology · doi:10.1093/rheumatology/kev269 · Cited by 171
Furst, D. E. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.019 · Cited by 171
On-demand anakinra treatment is effective in mevalonate kinase deficiency
Bodar, E. J., Kuijk, L. M., Drenth, J. P. H., van der Meer, J. W. M., Simon, A., & Frenkel, J. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.149922 · Cited by 168
Tumor Necrosis Factor and Tuberculosis
Lin, P. L., Plessner, H. L., Voitenok, N. N., & Flynn, J. L. (2007) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650027 · Cited by 167
Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
El-Osta, H. E., & Kurzrock, R. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0212 · Cited by 158
Santantonio, T. A., Fasano, M., Sinisi, E., Guastadisegni, A., Casalino, C., Mazzola, M., Francavilla, R., & Pastore, G. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.11.021 · Cited by 151
Regulation of the acute phase and immune responses: interleukin-6.
Sehgal, P. B. (1989) · PubMed · Cited by 148
A case of macrophage activation syndrome successfully treated with anakinra
Kelly, A., & Ramanan, A. V. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0919 · Cited by 147
Crown, J., Jakubowski, A., Kemeny, N., Gordon, M., Gasparetto, C., Wong, G., Sheridan, C., Toner, G., Meisenberg, B., & Botet, J. (1991) · Blood · doi:10.1182/blood.v78.6.1420.1420 · Cited by 142
Bruck, N., Suttorp, M., Kabus, M., Heubner, G., Gahr, M., & Pessler, F. (2011) · JCR: Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318205092d · Cited by 142
Koné‐Paut, I., Lachmann, H. J., Kuemmerle-Deschner, J. B., HACHULLA, E., Leslie, K. S., Mouy, R., Ferreira, A., Lheritier, K., Patel, N. P., Preiss, R., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3535 · Cited by 141
Shimizu, M., Nakagishi, Y., Kasai, K., Yamasaki, Y., Miyoshi, M., Takei, S., & Yachie, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.02.006 · Cited by 136
Dinarello, C. A., Rosenwasser, L. J., & Wolff, S. M. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.6.2517 · Cited by 131
Seckinger, P., Zhang, J. H., Hauptmann, B., & Dayer, J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5188 · Cited by 131
Pugliese, D., Guidi, L., Ferraro, P. M., Marzo, M., Felice, C., Celleno, L., Landi, R., Andrisani, G., Pizzolante, F., Vitis, I. D., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13352 · Cited by 121
Kuemmerle-Deschner, J. B., Ramos, E., Blank, N., Roesler, J., Felix, S. D., Jung, T., Stricker, K., Chakraborty, A., Tannenbaum, S., Wright, A. M., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3266 · Cited by 121
An Expanding Role for Interleukin-1 Blockade from Gout to Cancer
Dinarello, C. A. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00232 · Cited by 120
Schumacher, H. R., Evans, R. R., Saag, K. G., Clower, J., Jennings, W., Weinstein, S. P., Yancopoulos, G. D., Wang, J., & Terkeltaub, R. (2012) · Arthritis Care & Research · doi:10.1002/acr.21690 · Cited by 119
Risk of infections in rheumatoid arthritis patients treated with tocilizumab
Lang, V. R., Englbrecht, M., Rech, J., Nüsslein, H., Manger, K., Schuch, F., Tony, H.-P., Fleck, M., Manger, B., Schett, G., et al. (2012) · Rheumatology · doi:10.1093/rheumatology/ker223 · Cited by 119
IL-1β Receptor Antagonist Reduces Inflammation in Hemodialysis Patients
Hung, A. M., Ellis, C. D., Shintani, A., Booker, C., & Ikizler, T. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010070760 · Cited by 117
Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
Ottaviani, S., Moltó, A., Ea, H.-K., Neveu, S., Gill, G., Brunier, L., Palazzo, E., Meyer, O., Richette, P., Bardin, T., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4303 · Cited by 115
Knowledge and beliefs about cancer in a socioeconomically disadvantaged population
Loehrer, P. J., Greger, H. A., Weinberger, M., Musick, B. S., Miller, M. E., Nichols, C. R., Bryan, J., Higgs, D., & Brock, D. (1991) · Cancer · doi:10.1002/1097-0142(19911001)68:7<1520::aid-cncr2820680710>3.0.co;2-2 · Cited by 112
Mackey, A. C., Green, L., Leptak, C., & Avigan, M. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181957a11 · Cited by 111
Stankovic, K., Delmas, Y., Ureña, P., Peltier, J., Pellé, G., Jéru, I., Colombat, M., & Grateau, G. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr528 · Cited by 110
Church, L. D., & McDermott, M. (2009) · PubMed · Cited by 110
Gottlieb, A. B., Cooper, K. D., McCormick, T. S., Toichi, E., Everitt, D. E., Frederick, B., Zhu, Y., Pendley, C. E., Graham, M. A., & Ann Mascelli, M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182112 · Cited by 105
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Deisseroth, A., Ko, C.-W., Nie, L., Zirkelbach, J. F., Zhao, L., Bullock, J., Mehrotra, N., Del Valle, P., Saber, H., Sheth, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1678 · Cited by 105
Yokota, S., Itoh, Y., Morio, T., Sumitomo, N., Daimaru, K., & Minota, S. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.140288 · Cited by 104
Lebwohl, M., Emer, J. J., & Koutruba, N. (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5599 · Cited by 102
Laskari, K., Tzioufas, A. G., & Moutsopoulos, H. Μ. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3366 · Cited by 102
Song, L., Smith, M. A., Doshi, P., Sasser, K., Fulp, W., Altiok, S., & Haura, E. B. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000193 · Cited by 97
Current treatments for chronic hepatitis B virus infections
Zoulim, F., Lebossé, F., & Levrero, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.004 · Cited by 97
Tsai, T., Ho, V., Song, M. W., Szapary, P. O., Kato, T., Wasfi, Y. S., Li, S., Shen, Y., Leonardi, C., on behalf of the PHOENIX 1, P. 2., et al. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11142.x · Cited by 96
Obici, L. P., Meini, A., Cattalini, M., Chicca, S., Galliani, M., Donadei, S., Plebani, A., & Merlini, G. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.143438 · Cited by 93
Macrophage Activation Syndrome Treated with Anakinra
DURAND, M., TROYANOV, Y., LAFLAMME, P., & GREGOIRE, G. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.091046 · Cited by 86
Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome
Kimberley, F. C., Lobito, A. A., Siegel, R. M., & Screaton, G. R. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2197 · Cited by 84
Demyelinating events in rheumatoid arthritis after drug exposures
Bernatsky, S., Renoux, C., & Suissa, S. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.111500 · Cited by 80
Cell-type–restricted anti-cytokine therapy: TNF inhibition from one pathogenic source
Efimov, G. A., Kruglov, A., Khlopchatnikova, Z. V., Rozov, F. N., Mokhonov, V. V., Rose‐John, S., Scheller, J., Gordon, S., Stacey, M. A., Drutskaya, M. S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520175113 · Cited by 78
Interleukin-6 biology is coordinated by membrane bound and soluble receptors.
Rose-John, S. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3654 · Cited by 76
Management of rheumatic disease with comorbid HBV or HCV infection
Vassilopoulos, D., & Calabrese, L. H. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.63 · Cited by 76
Federici, S., Martini, A., & Gattorno, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00351 · Cited by 73
O’Toole, A., Lucci, M., & Korzenik, J. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4007-z · Cited by 73
Rider, P., Kaplanov, I., Romzova, M., Bernardis, L., Braiman, A., Voronov, E., & Apte, R. N. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00290 · Cited by 68
Self-citationTumor necrosis factor as a pharmacological target
Ghezzi, P., & Cerami, A. (2005) · Molecular Biotechnology · doi:10.1385/mb:31:3:239 · Cited by 66
DOYLE, M. V., Lee, M. T., & Fong, S. K. (1985) · PubMed · Cited by 64
Dallocchio, A., Canioni, D., Ruemmele, F. M., Duquesne, A., Scoazec, J., Bouvier, R., Paraf, F., Languepin, J., Wouters, C. H., Guillot, M., et al. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq136 · Cited by 60
Settas, L., Tsimirikas, G., Vosvotekas, G., Triantafyllidou, E., & Nicolaides, P. (2007) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31812e00a1 · Cited by 57
Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA)
Ohlsson, V., Baildam, E. M., Foster, H., Jandial, S., Pain, C. E., Strike, H., & Ramanan, A. V. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/ken030 · Cited by 55
Gottlieb, A. B., Langley, R. G. B., Philipp, S., Sigurgeirsson, B., Blauvelt, A., Martin, R., Papavassilis, C., & Mpofu, S. (2015) · PubMed · Cited by 52
Treatment of Psoriasis and Psoriatic Arthritis
Papoutsaki, M., & Costanzo, A. (2013) · BioDrugs · doi:10.1007/bf03325637 · Cited by 49
Siltuximab: First Global Approval
Markham, A., & Patel, T. (2014) · Drugs · doi:10.1007/s40265-014-0249-x · Cited by 48
Hyper-IgD syndrome or mevalonate kinase deficiency
Stoffels, M., & Simon, A. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328349c3b1 · Cited by 48
On-demand treatment with anakinra: a treatment option for selected TRAPS patients: Fig. 1
Grimwood, C., Despert, V., Jéru, I., & Hentgen, V. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev111 · Cited by 46
Cavarretta, I. T. R., Neuwirt, H., Zaki, M. H., Steiner, H., Hobisch, A., Nemeth, J. A., & Čulig, Z. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_56 · Cited by 44
A trial of recombinant human interleukin‐1 in patients with severe refractory aplastic anaemia
Walsh, C., Liu, J. M., Anderson, S. M., Rossio, J. L., Nienhuis, A. W., & Young, N. S. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb06408.x · Cited by 44
Interleukin-1α neutralisation in patients with cancer
Dinarello, C. A. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70164-0 · Cited by 37
Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud's disease.
Metyas, S., & Hoffman, H. M. (2006) · PubMed · Cited by 32
HARTMANN, L. C., Urba, W. J., Steis, R., Smith, J. W., VanderMolen, L. A., Creekmore, S. P., Sznol, M., CASCIANO, M. A., ENGLER, N., & LONGO, D. L. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.15.1190 · Cited by 26
T Helper Subsets, Peripheral Plasticity, and the Acute Phase Protein,α1-Antitrypsin
Baranovski, B. M., Freixo-Lima, G. S., Lewis, E. C., & Rider, P. (2015) · BioMed Research International · doi:10.1155/2015/184574 · Cited by 26
Self-citationMevalonate kinase deficiency syndrome with structural damage responsive to anakinra
Lequerre, T., Vittecoq, O., Pouplin, S., Klemmer, N., Mejjad, O., Daragon, A., Prieur, A., & Loët, X. L. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kem258 · Cited by 23
Direz, G., Noël, N., Guyot, C., Toupance, O., Salmon, J., & Eschard, J. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2012.04.009 · Cited by 20
Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra
Peciuliene, S., Burnytė, B., Gudaitienė, R., Rusonienė, S., Drazdienė, N., Liubšys, A., & Utkus, A. (2016) · Pediatric Rheumatology · doi:10.1186/s12969-016-0081-9 · Cited by 20
Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation
Andrés, M., & Pascual, E. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202087 · Cited by 18
Cohen, I., Rider, P., Vornov, E., Tomáš, M., Tudor, C., Wegner, M., Brondani, L., Freudenberg, M. A., Mittler, G., Ferrando‐May, E., et al. (2016) · Scientific Reports · doi:10.1038/srep19100 · Cited by 18
Self-citationRaheel, S., Crowson, C. S., Wright, K., & Matteson, E. L. (2016) · International Journal of Rheumatology · doi:10.1155/2016/4609486 · Cited by 18
Canakinumab for the treatment of cryopyrin-associated periodic syndromes
Walsh, G. M. (2009) · Drugs of today · doi:10.1358/dot.2009.45.10.1436882 · Cited by 17
Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
Dao, H., & Ren, V. Z. (2013) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s42424 · Cited by 16
Campanilho‐Marques, R., & Brogan, P. A. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2523-4 · Cited by 15
Canakinumab for the cryopyrin-associated periodic syndromes
Savic, S., & McDermott, M. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.195 · Cited by 14
Cattalini, M., Meini, A., Monari, P., Gualdi, G., Arisi, M., Pelucchi, F., Bolognini, S., Gattorno, M., Calzavara‐Pinton, P., & Plebani, A. (2013) · Dermatology Online Journal · doi:10.5070/d31911020405 · Cited by 14
Perrin, F., Néel, A., Graveleau, J., Ruellan, A., MASSEAU, A., & Hamidou, M. A. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2013.06.028 · Cited by 13
Thomas, S. K., Suvorov, A., Noens, L. A., Rukavitsin, O., Fay, J. W., Wu, K. L., Zimmerman, T. M., de Velde, H. J. V., Bandekar, R. R., Puchalski, T. A., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2314-7 · Cited by 13
Turesson, C., & Riesbeck, K. (2004) · PubMed · Cited by 10
IL-1 Receptor Antagonist Chimeric Protein: Context-Specific and Inflammation-Restricted Activation
Rider, P., Carmi, Y., Yossef, R., Guttman, O., Eini, H., Azam, T., Dinarello, C. A., & Lewis, E. C. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501168 · Cited by 9
Self-citationAcute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
Choi, J., Lee, J. S., Paik, W. H., Song, T. J., Kim, J. W., Bae, W. K., Kim, K., & Kim, J. G. (2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.22.1.168 · Cited by 7
Siltuximab in transplant-ineligible patients with myeloma
Bagcchi, S. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70226-8 · Cited by 5
Research works printed but not linked: 13
- 1985, Journal of Biological Response Modifiers, 4, 96
- 10.1002/1097-0142(19911001)68:760;1520::aid-cncr282068071062;3.0.co;2-2 · doi:10.1002/1097-0142(19911001)68:760;1520::aid-cncr282068071062;3.0.co;2-2
- 10.1002/1097-0215(20001101)88:3<lt;497::aid-ijc27>3.0.co;2-j · doi:10.1002/1097-0215(20001101)88:3<lt;497::aid-ijc27>3.0.co;2-j
- 2009, Cochrane Database of Systematic Reviews (Online), CD005121
- 2006, Journal of Rheumatology, 33, 2085
- 2004, Journal of Rheumatology, 31, 1876
- 10.1396674/dot.2009.45.10.1416583 · doi:10.1396674/dot.2009.45.10.1416583
- 2009, Current Opinion in Molecular Therapeutics, 11, 81
- 2013, Dermatology Online Journal, 19
- 2003, Journal of Rheumatology, 30, 1426
- 2014, The Lancet Oncology, 15
- 2010, Therapeutics and Clinical Risk Management, 6, 123
- 2015, Journal of Drugs in Dermatology, 14, 821
Cited by
Cytokines: From Clinical Significance to Quantification
Liu, C., Chu, D., Kalantar‐Zadeh, K., George, J., Young, H. A., & Liu, G. (2021) · Advanced Science · doi:10.1002/advs.202004433 · Cited by 940
Han, X., Xu, T., Fang, Q., Zhang, H., Yue, L., Hu, G., & Sun, L. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102010 · Cited by 544
Han, X., Sun, S., Sun, Y., Song, Q., Zhu, J., Song, N., Chen, M., Sun, T., Xia, M., Ding, J., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1596481 · Cited by 408
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Emerging principles of cytokine pharmacology and therapeutics
Saxton, R. A., Glassman, C. R., & Garcia, K. C. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00557-6 · Cited by 215
Metadata
- Authors
- Rider, P., Carmi, Y., & Cohen, I.
- Affiliations
- Tel Aviv University (IL)
- Western Galilee Hospital (IL)
- Corresponding author
- Cohen, Idan
- Venue
- International Journal of Cell Biology
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-11
- ISSN
- 1687-8876 (ISSN-L)
- 1687-8884
- PMC
- PMC5204077
- OpenAlex
- W2561062294
- Cited by
- 226
- References
- 157
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 13 · 2023: 17 · 2022: 23 · 2021: 39 · 2020: 32 · 2019: 17 · 2018: 27 · 2017: 9
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Cell Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Aliyah and Immigrant Absorption
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- inflammatory cytokines, biologic drugs, anti-TNF antibodies, interleukin-1 receptor antagonist, anti-IL-1 antibodies, anti-IL-6 receptor antibody, cytokine inhibition, autoimmunity, cancer, infection susceptibility, clinical risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.